Acquisition by Wright Timothy R of 21250 shares of Protagenic Therapeutics at 1.74 subject to Rule 16b-3
| PTIX Stock | USD 0.65 0.04 6.56% |
Slightly above 55% of Protagenic Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Protagenic Therapeutics suggests that some traders are interested. Protagenic Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Protagenic Therapeutics' earnings reports, geopolitical events, and overall market trends.
Protagenic |
Filed transaction by Protagenic Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Protagenic Therapeutics Fundamental Analysis
We analyze Protagenic Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagenic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagenic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Protagenic Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Protagenic Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Protagenic Therapeutics stock to make a market-neutral strategy. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics with similar companies.
Peers
Protagenic Therapeutics Related Equities
| ANTX | AN2 Therapeutics | 8.94 | ||||
| TPST | Tempest Therapeutics | 2.25 | ||||
| AVTE | Aerovate Therapeutics | 1.92 | ||||
| ACRV | Acrivon Therapeutics, | 1.71 | ||||
| RZLT | Rezolute | 1.03 | ||||
| SBHMY | Sino Biopharmaceutica | 0.00 | ||||
| XOMAO | XOMA | 0.32 | ||||
| ELDN | Eledon Pharmaceuticals | 1.47 | ||||
| ADAG | Adagene | 3.10 |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.